Apellis Pharmaceuticals Net Income vs. Current Valuation

APLS Stock  USD 26.33  0.57  2.12%   
Based on Apellis Pharmaceuticals' profitability indicators, Apellis Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Apellis Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2014-06-30
Previous Quarter
-37.7 M
Current Value
-57.4 M
Quarterly Volatility
73.3 M
 
Yuan Drop
 
Covid
At this time, Apellis Pharmaceuticals' Days Sales Outstanding is comparatively stable compared to the past year. EV To Sales is likely to gain to 30.83 in 2025, whereas Operating Cash Flow Sales Ratio is likely to drop (1.81) in 2025. At this time, Apellis Pharmaceuticals' Income Tax Expense is comparatively stable compared to the past year. Interest Income is likely to gain to about 25.3 M in 2025, despite the fact that Operating Income is likely to grow to (442.1 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.990.98
Fairly Up
Slightly volatile
For Apellis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Apellis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Apellis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Apellis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Apellis Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Apellis Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.99)
Revenue Per Share
5.811
Quarterly Revenue Growth
0.783
Return On Assets
(0.16)
Return On Equity
(1.07)
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Apellis Pharmaceuticals Current Valuation vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Apellis Pharmaceuticals is rated below average in net income category among its peers. It is rated fifth in current valuation category among its peers . At this time, Apellis Pharmaceuticals' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Apellis Current Valuation vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Apellis Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(528.63 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Apellis Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
3.42 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Apellis Current Valuation vs Competition

Apellis Pharmaceuticals is rated fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 38.23 Billion. Apellis Pharmaceuticals holds roughly 3.42 Billion in current valuation claiming about 9% of equities under Health Care industry.

Apellis Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Apellis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Apellis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Apellis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Apellis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.2 M-3 M
Operating Income-465.4 M-442.1 M
Income Before Tax-473.8 M-450.2 M
Total Other Income Expense Net-8.4 M-8.9 M
Net Loss-475.8 M-452 M
Net Loss-475.8 M-452 M
Net Loss-587 M-557.6 M
Income Tax Expense2.5 M2.6 M
Net Interest Income-7.8 M-8.2 M
Interest Income24.1 M25.3 M
Change To Netincome174.9 M183.7 M
Net Loss(5.12)(5.38)
Income Quality 1.01  0.65 
Net Income Per E B T 0.90  0.80 

Apellis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Apellis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Apellis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Apellis Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Apellis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now

   

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Use Investing Themes to Complement your Apellis Pharmaceuticals position

In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ISP Thematic Idea Now

ISP
ISP Theme
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.